Latest Breaking News On - Brii biosciences bio - Page 1 : comparemela.com

VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences

CAMBRIDGE, Mass., February 14, 2024 VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI" or the "Company"), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced agreements whereby Brii Biosciences ("Brii Bio"), subject to certain activities, is expected to: (i) acquire the intellectual property for VBI-2601, VBI’s HBV immunotherapeutic development program, and eliminate payment obligations from the July 2023 agreements between VBI a

United statesUnited kingdomNicole andersonPrehevbrio prehevbriAsia pacificBrii bioBrii biosciences bioJeff baxterCorporate communicationsVaccines incCompany quarterly reports on formBrii biosciencesPrivate securities litigation reform actAnnual reportQuarterly reportsVbi vaccines

VBI Vaccines (VBIV) to Sell Manufacturing Capabilities, Certain Related Assets, Enters New License Agreement with Brii Biosciences

VBI Vaccines (VBIV) to Sell Manufacturing Capabilities, Certain Related Assets, Enters New License Agreement with Brii Biosciences
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomBrii biosciences bioJeff baxterBrii bioVaccines incVbi vaccines incBrii biosciencesAsia pacific

VBI Vaccines Reports Third Quarter 2023 Financial Results

PreHevbrio global net revenue increased 52% quarter-over-quarter from Q2 to Q3 2023 Continued execution across earlier-stage pipeline, including: Initiation of Phase 2b study of VBI-1901 in.

United kingdomUnited statesHa afonBrii biosciences bioJeff baxterPrehevbrio prehevbriBrii bioEuropean union economic areaDelivery networks idnsAssociation withReconciliations of the companyKey program achievementsCoalition for epidemic preparedness innovationsForeign exchange lossVaccines incTechnology platform

VBI Vaccines Reports Second Quarter 2023 Financial Results

PreHevbrio global net revenue increased 48% quarter-over-quarter from Q1 to Q2 2023 - redefined, highly targeted commercial field team deployed at the end of Q2 Expanded hepatitis B. -Today at 08:04 am- MarketScreener

United kingdomUnited statesAsia pacificPrehevbrio prehevbriBrii bioBrii biosciencesBrii biosciences bioJeff baxterDelivery networks idnsForeign exchange lossNational research council of canadaNet loss excluding foreign exchangeVaccines incShare excluding foreign exchange lossReconciliations of the companyCompany quarterly reports on form

Brii Biosciences Broadens its Leadership in Hepatitis B with a Portfolio Now Addressing Disease s Burdens from Prevention to Cure

Brii Biosciences Broadens its Leadership in Hepatitis B with a Portfolio Now Addressing Disease s Burdens from Prevention to Cure
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New zealandRepublic ofSouth koreaUnited statesUnited kingdomBrii biosciences bioZhi hongAsia pacificBrii bioWorld health organizationVaccines incHepatitisb world health organizationPrnewswire brii biosciences limited bioBrii biosciencesEuropean union economic areaHepatitis world health organization